Glucotrack’s implantable blood glucose monitor successfully met the primary safety endpoints of its first human clinical study, the New Jersey company announced this month. The positive study result brings Glucotrack “one step closer” to providing an implantable alternative for continuous glucose monitoring (CGM) in people with diabetes, said the company.
The trial assessed the safety and procedural aspects of implanting, use, and removal of its continuous blood glucose monitor (CBGM) sensor lead. It did not assess the accuracy of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?